Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).

Russell Petty ,Wasat Mansoor,Zosia Miedzybrodzka,Ian Chau,Angel Garcia-Alonso,Mark Harrison,Doreen Massie,Anirban Chatterjee,Diane Collinson,Aileen Osbourne,Stephen Falk,Joyce Thompson ,Graeme I Murray ,David A Stevenson ,Susan Dutton ,Åsa Dahle-Smith ,Caroline Clark ,D Fyfe ,Seanmp Elyan ,David Ferry

doi:10.1200/jco.2014.32.15_suppl.4016

Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).

Russell Petty , Wasat Mansoor + Show 18 more

https://doi.org/10.1200/jco.2014.32.15_suppl.4016

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2014
Citations: 13

Affiliation: University of Aberdeen, The Christie NHS Foundation Trust, The Christie Hospital, Royal Marsden NHS Foundation Trust, Velindre Cancer Centre, Mount Vernon Hospital, NHS Grampian, Royal Shrewsbury Hospital, At Bristol, Heartlands Hospital, University of Oxford, Royal Lancaster Infirmary, Cheltenham General Hospital, New Cross Hospital

#Growth Factor Receptor Copy Number #Epidermal Growth Factor Receptor Copy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

4016 Background: The Cancer Oesophagus Gefitinib (COG) trial randomised (1:1) 450 patients(pts) with advanced EC who had progressed after 1-2 lines of chemotherapy to gefitinib (G) or placebo (P). ...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.